S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
"Prepare for Five Years of Famine" (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
A 100% Win Rate In 2022… (Ad)pixel
3 Undervalued Dividend Payers For Volatile Market Conditions
Don't Be Fooled by These 3 Value Traps
"Prepare for Five Years of Famine" (Ad)
The Bottom Is In For McCormick & Company
3 More Downgrades To Put On Your Buy List 
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
"Prepare for Five Years of Famine" (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
A 100% Win Rate In 2022… (Ad)pixel
3 Undervalued Dividend Payers For Volatile Market Conditions
Don't Be Fooled by These 3 Value Traps
"Prepare for Five Years of Famine" (Ad)
The Bottom Is In For McCormick & Company
3 More Downgrades To Put On Your Buy List 
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
"Prepare for Five Years of Famine" (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
A 100% Win Rate In 2022… (Ad)pixel
3 Undervalued Dividend Payers For Volatile Market Conditions
Don't Be Fooled by These 3 Value Traps
"Prepare for Five Years of Famine" (Ad)
The Bottom Is In For McCormick & Company
3 More Downgrades To Put On Your Buy List 
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
"Prepare for Five Years of Famine" (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
A 100% Win Rate In 2022… (Ad)pixel
3 Undervalued Dividend Payers For Volatile Market Conditions
Don't Be Fooled by These 3 Value Traps
"Prepare for Five Years of Famine" (Ad)
The Bottom Is In For McCormick & Company
3 More Downgrades To Put On Your Buy List 

Log in to MarketBeat

or
Google iconSign in with Google
or
Google iconSign in with Google
By creating a free account, you agree to our terms of service.
Sign in to your free account to enjoy these benefits
  • In-depth profiles and analysis for 20,000 public companies.
  • Real-time analyst ratings, insider transactions, earnings data, and more.
  • Our daily ratings and market update email newsletter.
Sign in to your free account to enjoy all that MarketBeat has to offer.